TEVA PHARMACEUTICAL INDUSTRIES LIMITED Operating Lease, Payments
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Operating Lease, Payments of $136.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-03
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED operating lease, payments for the quarter ending 2019-12-31 was $39.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED operating lease, payments for the quarter ending 2019-09-30 was $51.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED operating lease, payments for the quarter ending 2019-06-30 was $40.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED operating lease, payments for the quarter ending 2019-03-31 was $39.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED operating lease, payments for fiscal 2025 was $136.00M, a 4.90% decline from fiscal 2024.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED operating lease, payments for fiscal 2024 was $143.00M, a 1.42% increase from fiscal 2023.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED operating lease, payments for fiscal 2023 was $141.00M, a 0.71% increase from fiscal 2022.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED operating lease, payments for fiscal 2022 was $140.00M, a 2.10% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $136.00M 10-K · filed 2026-02-03 | |||
| 2024-12-31 | $143.00M 10-K · filed 2026-02-03 | |||
| 2023-12-31 | $141.00M 10-K · filed 2026-02-03 | |||
| 2022-12-31 | $140.00M 10-K · filed 2025-02-05 | |||
| 2021-12-31 | $143.00M 10-K · filed 2024-02-12 | |||
| 2020-12-31 | $151.00M 10-K · filed 2023-02-10 | |||
| 2019-12-31 | $39.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $90.00M derived: sum of 2 quarters · filed 2022-02-09 | $130.00M derived: sum of 3 quarters · filed 2022-02-09 | $169.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $51.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $91.00M derived: sum of 2 quarters · filed 2019-11-07 | $130.00M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $40.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $79.00M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $39.00M 10-Q · filed 2019-05-02 |